Document Type : Original Article
Authors
- Mohsen Mohammadi 1
- Seyedeh Mahdieh Namayandeh 2
- Masoud Mirzaei 1
- Mohsen Askari Shahi 1
- Seyed Mahmoud Sadr Bafighi 3
- Hamidreza Dehghan 4
1 Center For Healthcare Data Modeling, Departments of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 Center For Healthcare Data Modeling, Departments of Biostatistics and Epidemiology, School of Public Health, Afshar Research Development Center, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Department of Cardiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4 Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract
BACKGROUND: The purpose of this study was estimate and identify in hospital mortality predictors factors for patients with acute ST elevation myocardial infarction (STEMI).
METHODS: This study is a retrospective cohort study based on data from the Yazd Cardiovascular Diseases Registry (YCDR) from 2015-2018 in Yazd Province, Iran, focusing on hospitalized patients with ST-elevation myocardial infarction (STEMI). The primary outcome was in-hospital mortality in STEMI patients. A total of 1861 patients with STEMI were analyzed. Multivariable logistic regression was used to determine death predictive factors for in-hospital mortality in STEMI patients. The significance level of the model was considered to be 5% and the software was used for analysis.
RESULTS: The study included 1,861 patients with STEMI. Among them, 103 (5.5%) individuals died during admission the hospital. After multivariable logistic regression, the following variables were identified as death predictive factors for in-hospital mortality of STEMI: having a history of CVA (OR: 5.6, 95% CI: 2.2-20.3), killip class IV (OR: 6.4, 95%CI: 1.5-11.2), lower ejection fraction (OR: 3.6, 95% CI: 1.2-9.8), lower HDL cholesterol (OR: 1.2, 95% CI: 1.01-2.3), and lower hemoglobin (OR: 1.4, 95% CI: 1.3-2.9).
CONCLUSION: This study found that lower ejection fraction, lower hemoglobin levels, Killip class IV, having a history of CVA, and low HDL cholesterol levels are important death predictive factors for hospital mortality in patients with STEMI. Health policy in STEMI management must consider these factors to improve hospital prognosis.
Keywords
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Nov 27;104(22):2746-53. https://doi.org/10.1161/hc4601.099487
3. White HD, Thygesen K, Alpert JS, Jaffe AS. Republished: clinical implications of the third universal definition of myocardial infarction. Postgrad Med J. 2014 Sep;90(1067):502-10. https://doi.org/10.1136/postgradmedj-2012-302976rep
4. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. https://doi.org/10.1093/eurheartj/ehs184
5. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015 Apr 2;372(14):1333-41. https://doi.org/10.1056/nejmoa1406656
6. Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J. 2010 Jan;74(1):93-100. https://doi.org/10.1253/circj.cj-09-0619
7. Saeedi MY, Alsafi YH, Afghan SZ, Al-Khudair SS, Al-Dhwailea SK, Badawi AA. Cardiovascular risk assessment in general population at primary health care centers in Saudi Arabia: Using the World Health Organization/International Society of Hypertension risk prediction charts. Int Res J Public Environ Health. 2018 Mar;5(3):46-51. https://doi.org/10.15739/irjpeh.18.008
8. Rahimi K, Duncan M, Pitcher A, Emdin CA, Goldacre MJ. Mortality from heart failure, acute myocardial infarction and other ischaemic heart disease in England and Oxford: a trend study of multiple-cause-coded death certification. J Epidemiol Community Health. 2015 Oct;69(10):1000-5. https://doi.org/10.1136/jech-2015-205689
9. Fahimfar N, Khalili D, Sepanlou SG, Malekzadeh R, Azizi F, Mansournia MA, et al. Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium. BMJ open. 2018;8(7):e020303. https://doi.org/10.1136/bmjopen-2017-020303
10. Tsien CL, Fraser HS, Long WJ, Kennedy RL. Using classification tree and logistic regression methods to diagnose myocardial infarction. Stud Health Technol Inform. 1998;52 Pt 1:493-7.
11. Gregg RE, Babaeizadeh S. Detection of culprit coronary lesion location in pre-hospital 12-lead ECG. J Electrocardiol. 2014 Nov-Dec;47(6):890-4. https://doi.org/10.1016/j.jelectrocard.2014.07.014
12. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008 Dec 16;3:17. https://doi.org/10.1186/1751-0473-3-17
13. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020 Aug 4;324(5):488-504. https://doi.org/10.1001/jama.2020.10262
14. Alkhalil M, Kearney A, MacElhatton D, Fergie R, Dixon L. The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction. Int J Cardiol. 2020 Dec 15;321:12-7. https://doi.org/10.1016/j.ijcard.2020.07.001
15. Thuijs DJFM, Milojevic M, Stone GW, Puskas JD, Serruys PW, Sabik JF 3rd, et al. Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. Eur J Heart Fail. 2020 May;22(5):871-9. https://doi.org/10.1002/ejhf.1681
16. Toma A, Stähli BE, Gick M, Gebhard C, Kaufmann BA, Mashayekhi K, et al. Comparison of Benefit of Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients With Versus Without Reduced (≤40%) Left Ventricular Ejection Fraction. Am J Cardiol. 2017 Nov 15;120(10):1780-6. https://doi.org/10.1016/j.amjcard.2017.07.088
17. Daneault B, Généreux P, Kirtane AJ, Witzenbichler B, Guagliumi G, Paradis JM, et al. Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥ 40% (from the HORIZONS-AMI trial). Am J Cardiol. 2013 Jan 1;111(1):12-20. https://doi.org/10.1016/j.amjcard.2012.08.040
18. Liu Y, Song J, Wang W, Zhang K, Qi Y, Yang J, et al. Association of ejection fraction with mortality and cardiovascular events in patients with coronary artery disease. ESC Heart Fail. 2022;9(5):3461-8. https://doi.org/10.1002/ehf2.14063
19. Yeboah J, Rodriguez CJ, Qureshi W, Liu S, Carr JJ, Lima JA, et al. Prognosis of Low Normal Left Ventricular Ejection Fraction in an Asymptomatic Population-Based Adult Cohort: The Multiethnic Study of Atherosclerosis. J Card Fail. 2016 Oct;22(10):763-8. https://doi.org/10.1016/j.cardfail.2016.03.013
20. Toma M, Ezekowitz JA, Bakal JA, O’Connor CM, Hernandez AF, Sardar MR, et al. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. Eur J Heart Fail. 2014 Mar;16(3):334-41. https://doi.org/10.1002/ejhf.19
21. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar;9(3):e002744. https://doi.org/10.1161/circheartfailure.115.002744
22. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018 Dec;25(4):277-84. https://doi.org/10.1016/j.pathophys.2018.04.003
23. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017 Aug 24;3:17058. https://doi.org/10.1038/nrdp.2017.58
24. Abbate A, Arena R, Abouzaki N, Van Tassell BW, Canada J, Shah K, et al. Heart failure with preserved ejection fraction: refocusing on diastole. Int J Cardiol. 2015 Jan 20;179:430-40. https://doi.org/10.1016/j.ijcard.2014.11.106
25. Smiseth OA, Morris DA, Cardim N, Cikes M, Delgado V, Donal E, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):e34-61. https://doi.org/10.1093/ehjci/jeab154
26. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016 Dec 6;134(23):e535-78. https://doi.org/10.1161/cir.0000000000000450
27. Acharjee S, Roe MT, Amsterdam EA, Holmes DN, Boden WE. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2013 Oct 15;112(8):1057-62. https://doi.org/10.1016/j.amjcard.2013.05.050
28. Wolfram RM, Brewer HB, Xue Z, Satler LF, Pichard AD, Kent KM, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol. 2006 Sep 15;98(6):711-7. https://doi.org/10.1016/j.amjcard.2006.04.006
29. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. https://doi.org/10.1056/nejmoa064278
30. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, Lüscher TF, et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J. 2013 Dec;34(46):3557-62. https://doi.org/10.1093/eurheartj/eht163
31. Ouimet M, Barrett TJ, Fisher EA. HDL and Reverse Cholesterol Transport. Circ Res. 2019 May 10;124(10):1505-18. https://doi.org/10.1161/CIRCRESAHA.119.312617
32. Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflamm Res. 2018 May;67(5):391-405. https://doi.org/10.1007/s00011-018-1129-8
33. Rosenson RS, Brewer Jr HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016 Jan;13(1):48-60. https://doi.org/10.1038/nrcardio.2015.124
34. Colombo MG, Kirchberger I, Amann U, Heier M, Thilo C, Kuch B, et al. Association between admission anemia and long-term mortality in patients with acute myocardial infarction: results from the MONICA/KORA myocardial infarction registry. BMC Cardiovasc Disord. 2018 Mar 9;18(1):50. https://doi.org/10.1186/s12872-018-0785-5
35. Ducrocq G, Puymirat E, Steg PG, Henry P, Martelet M, Karam C, et al. Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry. Am Heart J. 2015 Oct;170(4):726-34.e2. https://doi.org/10.1016/j.ahj.2015.07.004
36. Uchida Y, Ichimiya S, Ishii H, Kanashiro M, Watanabe J, Hayano S, et al. Impact of Admission Anemia on Coronary Microcirculation and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Int Heart J. 2015;56(4):381-8. https://doi.org/10.1536/ihj.15-006
37. Ayhan E, Aycicek F, Uyarel H, Ergelen M, Cicek G, Gul M, et al. Patients with anemia on admission who have undergone primary angioplasty for ST elevation myocardial infarction: in-hospital and long-term clinical outcomes. Coron Artery Dis. 2011;22(6):375-9. https://doi.org/10.1097/mca.0b013e3283472ac5
38. Tomaszuk-Kazberuk A, Bolińska S, Młodawska E, Łopatowska P, Sobkowicz B, Musiał W. Does admission anaemia still predict mortality six years after myocardial infarction? Kardiol Pol. 2014;72(6):488-93. https://doi.org/10.5603/kp.a2014.0046
39. Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T, et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J. 2003 Dec;24(23):2142-50. https://doi.org/10.1016/j.ehj.2003.09.008
40. Li J, Jiang C, Lai Y, Li L, Zhao X, Wang X, et al. Association of On-Admission Anemia With 1-Year Mortality in Patients Hospitalized With Acute Heart Failure: Results From the HERO Study. Front Cardiovasc Med. 2022 May 4;9:856246. https://doi.org/10.3389/fcvm.2022.856246
41. Haubrich C, Kohnke A, Diehl RR, Möller-Hartmann W, Klötzsch C. Impact of vertebral artery disease on dynamic cerebral autoregulation. Acta Neurol Scand. 2005 Nov;112(5):309-16. https://doi.org/10.1111/j.1600-0404.2005.00498.x
42. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Nat Rev Cardiol. 2015 Nov;12(11):659-69. https://doi.org/10.1038/nrcardio.2015.109
43. Mozos I. Mechanisms linking red blood cell disorders and cardiovascular diseases. Biomed Res Int. 2015;2015:682054. https://doi.org/10.1155/2015/682054
44. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15 Suppl 3:14-8. https://doi.org/10.1093/oxfordjournals.ndt.a027970
45. Rashid M, Kwok CS, Gale CP, Doherty P, Olier I, Sperrin M, et al. Impact of co-morbid burden on mortality in patients with coronary heart disease, heart failure, and cerebrovascular accident: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2017 Jan 1;3(1):20-36. https://doi.org/10.1093/ehjqcco/qcw025
46. Pedrinelli R, Ballo P, Fiorentini C, Denti S, Galderisi M, Ganau A, et al. Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown). 2012 Mar;13(3):194-202. https://doi.org/10.2459/jcm.0b013e3283511ee2
47. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008 Jun;7(6):476-84. https://doi.org/10.1016/j.cmet.2008.03.010
48. Fini NA, Bernhardt J, Churilov L, Clark R, Holland AE. Adherence to physical activity and cardiovascular recommendations during the 2years after stroke rehabilitation discharge. Ann Phys Rehabil Med. 2021 Mar;64(2):101455. https://doi.org/10.1016/j.rehab.2020.03.018
49. Redfern J, Gallagher R, O’Neil A, Grace SL, Bauman A, Jennings G, et al. Historical Context of Cardiac Rehabilitation: Learning From the Past to Move to the Future. Front Cardiovasc Med. 2022 Apr 27;9:842567. https://doi.org/10.3389/fcvm.2022.842567
50. Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol. 2020 Nov 21;4:100130. https://doi.org/10.1016/j.ajpc.2020.100130
51. Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Inflammation and Cardiovascular Disease: The Future. Eur Cardiol. 2021 May 17;16:e20. https://doi.org/10.15420/ecr.2020.50
)